Ionis Pharmaceuticals price target lowered to $38 from $45 at Stifel

Stifel analyst Paul Matteis lowered the firm’s price target on Ionis Pharmaceuticals (IONS) to $38 from $45 and keeps a Hold rating on the shares following what the firm calls “a relatively in-line 4Q24 report.” The firm’s price target decrease is primarily driven by increased spending assumptions, the analyst tells investors.